ABSTRACT. Hyperlipidemia is prominent among the disturbances in intermediary metabolism that occur subsequent to infections by microorganisms. The response to such infections is known to involve several cell types and is m d i t e d by cytokines. We hypothesized that metabolic lipid disturbances seen during infection in cystic fibrosis (CF) patients may partly be the result of excessive tumor necrosis factor-a (TNF-a), a proinflammatory cytokine known to cause a large spectrum of pathophysiologic alterations, including impaired lipid metabolism. Therefore, we determined the circulating concentration of TNF-a and analyzed its relationship to lipid and lipoprotein levels, as well as lipoprotein lipase activity, in 31 CF patients. Plasma TNF-a values were significantly ( p < 0.01) elevated in patients with CF compared with controls. The CF subjects were found to have decreased plasma cholesterol (25%), LDL cholesterol (35%), and HDL cholesterol (19%) concentrations, whereas plasma triglycerides were significantly increased ( p < 0.001). The apo A-I level was reduced ( p < 0.005), whereas apo B levels were normal.
turbances result in repeated airway infections and obstruction, pancreatic insufficiency, and cirrhosis (I, 2). Advances in pancreatic enzyme replacement therapy have rendered pancreatic failure much less of a problem. Nevertheless, chronic respiratory disease, present in 95% of CF patients, remains the major cause of morbidity and mortality (1, 2). The secretion of dehydrated mucus impairs airway mucociliary clearance and predisposes patients to recurrent bronchial infections (3, 4) . The CF airway shows a particular propensity to colonization and recurrent infection with the bacterium Pseudomonas aeruginosa progressively destroying the lung, leading to respiratory failure (5, 6) . Chronic bacterial infections have been implicated in disturbances of intermediary metabolism, including hyperlipidemia. The chronic inflammatorv Drocess is accom~anied bv increased svstemic concentration; of inflammatoryA cytokines with diveke biologic effects. TNF-a, also termed cachectin, is a proinflammatory cytokine that has been implicated as an important mediator in several chronic inflammatory disorders (7, 8) . In addition to its central role in inflammation and immunity. T N F s numerous biologic effects include hyperlipidemia (9, 10) . TNFa causes an increase in triglycerides camed by VLDL as a result of the well-established inhibitory effects of TNF-a on lipoprotein lipase and hepatic lipogenesis ( l I-13).
We have recently shown that CF patients have abnormalities in lipoprotein concentration, composition, size, and metabolism (14. 15) . In addition to EFA deficiency. increased circulating levels of TNF in CF may provide an explanation for the lipid and lipoprotein derangement in CF. To verify this hypothesis, we determined the plasma levels of TNF-a in CF patients and evaluated the correlation between TNF-a and lipid and lipoprotein levels and their metabolism.
PATIENTS AND METHODS
Subjects. We randomly selected 3 1 young adolescent patients followed at the CF clinic of St.-Justine Hospital (age range 9 to 14 y; 18 males and 13 females). The diagnosis was based on the sweat chloride test and had been previously confirmed by family history of CF, clinical findings of typical pulmonary disease, and/or gastrointestinal disorders. Informed consent was obtained from the parents, and the project was approved by the Ethics Committee of St.-Justine Hospital. The group of CF patients was attending a CF outpatient clinic at the time of sampling. They were consuming a high-energy diet ( 150% of recommended daily allowance for age), composed of 45 to 50% carbohydrate, 15 to 20% protein, and 35 to 40% lipid. The intake of fat included a 10 to 15% EFA supplement (sunflower or corn oil). All the CF patients were maintained on multivitamin supplements, exogenous pancreatic enzymes, and oral antibiotics. Patient compliance with the dietary intake was evaluated closely by the team of nutritionists during many follow-up visits. When compared with controls (C), no abnormalities were noted in their percentThe plasma fatty acid pattern was also profoundly affected in age of ideal height 97.9 + 0.8 (C: 95-105) and percentage of CF patients ( The CF 2.2-and 3.6-fold, respectively ( p < 0.001). These marked alterpatient group had pancreatic insufficiency, as shown by steator-ations in fatty acids led to a 7-fold ( p < 0.005) elevation of the rhea (13.8 + 1.6 g/24 h), absent in all controls. Their chronic 20:3w9/20:4w6 ratio, a well-established index confirming EFA respiratory disease was stable with no evidence of pulmonary deficiency. Similarly, the 16: l w7/18:2w6 ratio, which has also exacerbation at the time of study (Schwachman score 77.4 + been shown to be a good discriminant for EFA deficiency. was 1.5). The CF subjects included EFA-sufficient and EFA-deficient four times higher in CF group than in controls ( p < 0.001).
patients. Healthy, age-matched controls (n = 39) were recruited
To assess the potential role of LPL activity in the abnormally for comparative study. They consisted of a group of normal elevated plasma triglyceride concentration, lipolytic activity was children undergoing dyslipidemia screening. Controls with ab-measured in plasma of CF and control patients (Fig. 1) . The normal plasma lipids or lipoprotein levels were excluded. hypertriglyceridemia, described above, was associated with a 3 1 % Lipid and lipoprotein anal.vses. Blood samples were collected decrease of total postheparin lipolytic activity, compared with in EDTA ( l mg/mL) after a 12-h overnight fast. Plasma was controls (9.40 + 1.02 versus 13.57 + 0.73 pmol FFA/mL/h, p < separated immediately by low-speed centrifugation ( I500 x g) at 0.005). Hepatic lipase activity was particularly affected in CF 4'C. The concentrations of total cholesterol and triglycerides patients (4.59 + 0.49 versus 8.61 + 0.63, p < 0.001).
were determined enzymatically using a commercial kit (BoehrinPlasma TNF-a concentrations ( Fig. 2) . determined by RIA.
ger Mannheim, Montreal, Canada) as reported previously (14. were significantly ( p < 0.01) increased (-3-fold) in CF patients 16). HDL cholesterol was quantified after the precipitation of compared with controls (82.7 + 8.4 verslrs 2 1.1 + 7.2 pg/mL).
VLDL and LDL with phosphotungstic acid (14, 16) . LDL cho-The relationship between plasma TNF-a and plasma triglycerides lesterol was measured by the method of Friedewald et al. (17) . is presented in Figure 3 . A significant correlation was found Quantitative measurements of apolipoprotein levels in whole between plasma triglycerides of CF patients and TNF-a ( r = plasma were carried out by nephelometry using a commercial 0.70, p < 0.001). whereas no correlation was detectable between standard supplied by Hoerscht-Behring (Quebec, Canada) (1 4). TNF-a levels and 18:2w6/20:4w6. 16: l w7/18:2~6, 20:3w9/ The plasma fatty acid composition was analyzed using methods 20:4w6, total postheparin lipolytic activity or extrahepatic lipowe have described previously ( 15) . protein lipase activity (Table 3) . However, a negative correlation Lipolytic activity measurement. For assay of lipolytic activities, was noted between TNF-a and total cholesterol ( r = 0.53. p < heparin was injected i.v. (10 U/kg body weight), and blood was 0.0025) as well as hepatic lipase activity ( r = 0.64, p < 0.0068). collected 10 min later into EDTA, as per our established method These correlation coefficients were more elevated ( r > 0.70) (14, 16) . Total lipolytic activity was measured in plasma with an when control values were included in the analysis. Furthermore. emulsion of tri[l-'4C]oleoylglycerol as substrate (18) . Hepatic exclusion of the patients with an outlying TNF-a levels above lipase was quantified in the presence of protamine sulfate, and 150 pg/mL did not remove the significance of the correlation extralipoprotein lipase activity was calculated as the difference between TNF-a and plasma triglycerides ( r = 0.52. p < 0.005).
between total lipase activity and hepatic lipase. The extraction of FFA was performed by the procedure of Belfrage and Vaughan ( 19) as previously described (20) .
DISCUSSION
QuantiJication of TNF-a. Plasma TNF-a concentrations were
The present study demonstrates that pediatric CF patients assayed by standard RIA kit (InterMed. Markham, Ontario. have markedly abnormal plasma fatty acid patterns, significant Canada) and expressed as pg/mL. alteration in lipid and lipoprotein concentrations, and lipoproStatistical anal.vsis. All values were assessed in duplicate and tein lipase impairment, in agreement with our previous findings are expressed as the mean + SEM. Statistical differences between (14, 15) . Our results reveal the presence of increased circulating means Were assessed using the two-tailed t test. Linear regression levels of TNF-a, a primary mediator in the pathogenesis of analysis was used to assess the correlation between values ex-infection, injury, and inflammation. Furthermore, the data obpressed in graphs as continuous functions.
tained suggest an association of elevated TNF-a with hypertriglyceridemia in CF patients.
RESULTS
The hypertriglyceridemia observed in CF patients is remarkable in that these patients often present with malabsorption and The patterns of plasma lipids, lipoproteins, and apoproteins malnutrition (2 1). CF patients are particularly prone to chronic for the CF patients and control groups are shown in Table I . pulmonary infection with P. aerzrginosa, the most prominant Mean plasma triglyceride levels were elevated in CF patients bacterial colonizer (4-6). One cytokine that is being increasingly ( p < 0.001) compared with controls. Furthermore, significant recognized as a central mediator in a wide spectrum of physiohypocholesterolemia characterized the CF group. and this was logic and immune functions is macrophage-derived TNF-a (22) . associated with a significant ( p < 0.001) decrease in both LDL The production or administration of high concentrations of cholesterol and HDL cholesterol fractions. The apo A-I concen-TNF-a can cause a large spectrum of metabolic and pathotration was reduced in CF patients ( p < 0.005). whereas apo B physiologic alterations, including acidosis (23) . elaboration of levels were similar to those in controls. stress hormones (24) . a decrease in the transmembrane potential -- of skeletal muscle (25) , and a decrease in blood glucose (26) . Similarly, the changes in lipid metabolism noted during infection are now known to be produced by cytokines (7) (8) (9) (10) . Increased hepatic lipid synthesis in vivo and decreased levels of lipoprotein lipase in certain adipose tissues in vifro and in vivo have been induced by several cytokines, including TNF-tu. These considerations prompted us to analyze the relationship between circulating TNF-n levels and plasma triglycerides in CF. We found that circulating TNF-tu levels were commonly elevated in patients with CF, and that there was a significant correlation between the absolute concentrations of TNF-tu and plasma triglycerides in such patients.
TNF-n may induce hypertriglyceridemia by its inhibitory effect on lipoprotein lipase activity, as well as its enhancement of hepatic lipogenesis ( l 1 -1 3). Decreases in lipoprotein lipase could lead to high plasma triglyceride levels by diminishing the clearance of triglyceride-rich lipoproteins. However, our results did not disclose any correlation between total or extrahepatic postheparin lipoprotein lipase activities and triglycerides or TNF-tu. Des~ite the absence of clinical or biochemical evidence of liver dysiunction in the CF group studied, hepatic lipase level was significantly reduced. However, only a negative correlation was found between hepatic lipase and plasma TNF-tu. Our observations are not at variance with recent data, indicating that TNF-tu may induce an increase in serum triglyceride levels in vivo by stimulating hepatic lipogenesis and VLDL production. However, these studies were unable to demonstrate that TNF-tu is an inhibitor of adipose tissue lipoprotein lipase activity and triglyceride clearance (26) . Also of interest are the observations of Suter cJ1 ul. (27) . showing elevated plasma levels ofother cytokines in CF, including IL-ltu and IL-Ip. Both 1L-I and interferon-tu have also been shown to stimulate hepatic lipogenesis (28) . Additional studies are obviously needed to further explore the significance and relationship between various cytokines and lipid metabolic abnormalities in CF patients.
The major effects of severe EFA deficiency include growth Failure, a scaly dermatitis, impaired development of reproductive systems, gastrointestinal tract dysfunction, and an increased basal metabolic rate (29, 30) . The CF group studied in this report was not different from controls with respect to growth parameters. In addition, EFA deficiency can decrease resistance to bacterial infection, aggravating the chronic respiratory disease associated with accumulation of tenacious, purulent exudate in secondary bronchi (3 I) . Given that linoleate and arachidonate are required for prostaglandin synthesis, their reduced availability in CF might decrease the formation of these biologically active substances with wide-spread physiologic consequences. Chase and Dupont (32) found that C F patients with low linoleic acid levels had increased prostaglandin F2,, whereas others have reported decreased prostaglandin F2,, (33). The latter prostaglandin appears to participate in the down-regulation of TNF-a expression and secretion. Prostaglandin E2 is known to inhibit the production of TNF-a by monocytes (34, 35) . Because prostaglandin E2 is an arachidonic acid metabolite, it was logical to examine the relationship between elevated TNF-a levels in C F patients with EFA deficiency. Our data did not, however, reveal a positive correlation between EFA deficiency and TNF-a. Future directions that need to be explored in the area of inflammation in CF include the relationship of EFA deficiency with other cytokines. This is particularly important in view of the available data demonstrating that prostaglandin Ez affects the activity of macrophages, resulting in reduced IL-I secretion and potentially impairing host immune response to infection.
The negative correlation found between circulating TNF-a levels and total cholesterol as well as hepatic lipase is intriguing. So far, we have no plausible explanation for these findings. Whether TNF-a reduces the synthesis of cholesterol or stimulates its degradation is not yet known. Harada et al. (36) have recently investigated the effects of recombinant human TNF-a on the cellular binding of human LDL to skin fibroblasts. Their results indicated that TNF-a increased LDL receptor activity, which might contribute to the rapid disappearance of peripheral cholesterol.
As mentioned before, CF patients are particularly prone to chronic pulmonary infections, with multiple cytokines produced by immune cells to eliminate invading microorganisms. Recently, it has been suggested that increased plasma triglyceride levels could be beneficial during infections. VLDL particles can protect from the toxicity of endotoxins secreted by microorganisms (37), and furthermore, HDL binds endotoxin (38). Other studies have shown that lipoproteins are able to inactivate viruses (39). These observations suggest that the hyperlipidemia occurring in CF is part of the body's host defense mechanisms.
In summary, our study demonstrated an abnormally elevated concentration of circulating TNF-a in CF patients. Our results suggest that TNF-a may participate in the hypertriglyceridemia of C F patients by stimulating hepatic lipogenesis rather than inhibiting TG clearance by lipoprotein lipase. Despite the detected correlation between TNF-a and hypertriglyceridemia, additional investigation is called for to identify the underlying mechanisms.
